The study, called TARGET-ASTHMA, is a longitudinal analysis that will extend three years retrospectively prior to patient consent and 10 years going forward, the company said in a news release.
Read More
Taarget PharmaSolutions names new CEO and a senior advisor.
Read More
Durham-based TARGET PharmaSolutions, a clinical data company focused on real-world evidence in disease studies, has launched a new observational study of several inflammatory skin conditions, initially focusing on eczema.
Read MoreThe two companies will team up on TARGET-IBD, a longitudinal observational study that evaluates patients with inflammatory bowel disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis.
Read More
Chapel Hill-based TARGET PharmaSolutions, a clinical data company focused on real-world evidence in disease studies, has formed a strategic partnership with Gilead Sciences to better understand two major liver disorders. Gilead is the sixth major pharmaceutical partner to join in TARGET-NASH, a study of nonalcoholic fatty liver disease, or nonalcoholic...
Read More
